Stock Scorecard



Stock Summary for Axogen Inc (AXGN) - $33.55 as of 12/8/2025 7:46:05 PM EST

Total Score

7 out of 30

Safety Score

43 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AXGN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AXGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AXGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AXGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AXGN (43 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 1
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for AXGN

Axogen (AXGN) Price Target Increased by 18.26% to 34.58 12/7/2025 3:44:00 AM
Axogen, Inc. Announces FDA Approval of Avance® Biologics License 12/5/2025 3:44:00 AM
Axogen (NASDAQ: AXGN) wins FDA Accelerated Approval for Avance nerve graft, eyes Q2 2026 launch 12/5/2025 3:44:00 AM
Axogen gets FDA OK for Avance’s biologics license application (AXGN:NASDAQ) 12/4/2025 12:13:00 PM
Axogen, Inc. Receives FDA Approval for AVANCE® Biologics License Application to Treat Peripheral Nerve Discontinuities 12/4/2025 1:10:00 AM
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) 12/3/2025 8:01:00 PM
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm 11/2/2025 11:34:00 AM
Axogen, Inc. Reports Third Quarter 2025 Financial Results 10/29/2025 7:00:00 AM
(AXGN) Risk Channels and Responsive Allocation 10/16/2025 6:26:00 PM
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 - The Manila Times 10/15/2025 11:04:00 AM

Financial Details for AXGN

Company Overview

Ticker AXGN
Company Name Axogen Inc
Country USA
Description AxoGen, Inc. is a leading medical technology company based in Alachua, Florida, dedicated to the innovation of surgical solutions for the reconstruction and repair of peripheral nerves damaged by injury or trauma. With a proprietary portfolio that includes advanced nerve grafts, conduits, and associated surgical products, AxoGen aims to enhance nerve regeneration and facilitate functional recovery for patients. As a frontrunner in the regenerative medicine arena, the company is well positioned to capitalize on the increasing demand for peripheral nerve repair solutions, thereby driving sustainable growth while significantly improving patient outcomes in this specialized healthcare market.
Sector Name HEALTHCARE
Industry Name MEDICAL DEVICES
Most Recent Quarter 9/30/2025
Next Earnings Date 3/3/2026

Stock Price History

Last Day Price 33.55
Price 4 Years Ago 9.37
Last Day Price Updated 12/8/2025 7:46:05 PM EST
Last Day Volume 838,061
Average Daily Volume 1,010,868
52-Week High 34.24
52-Week Low 9.22
Last Price to 52 Week Low 263.88%

Valuation Measures

Trailing PE N/A
Industry PE 44.99
Sector PE 89.35
5-Year Average PE 21.82
Free Cash Flow Ratio 64.52
Industry Free Cash Flow Ratio 27.28
Sector Free Cash Flow Ratio 28.79
Current Ratio Most Recent Quarter 4.09
Total Cash Per Share 0.52
Book Value Per Share Most Recent Quarter 2.62
Price to Book Ratio 12.72
Industry Price to Book Ratio 4.32
Sector Price to Book Ratio 33.16
Price to Sales Ratio Twelve Trailing Months 7.16
Industry Price to Sales Ratio Twelve Trailing Months 5.90
Sector Price to Sales Ratio Twelve Trailing Months 15.82
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 46,122,300
Market Capitalization 1,547,403,165
Institutional Ownership 92.94%

Dividends

Ex-Dividend Date 1/27/2010
Previous Dividend Amount 0.0000
Current Dividend Amount 1.0000
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 16.67
Forward Annual Dividend Yield 106.56%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 1,566.67%
3-Year Dividend Growth Rate Percentage 1,566.67%
5-Year Dividend Growth Rate Percentage 1,566.67%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 54.12%
Reported EPS 12 Trailing Months -0.05
Reported EPS Past Year 0.22
Reported EPS Prior Year 0.13
Net Income Twelve Trailing Months -2,097,000
Net Income Past Year -9,964,000
Net Income Prior Year -21,716,000
Quarterly Revenue Growth YOY 23.50%
5-Year Revenue Growth 11.91%
Operating Margin Twelve Trailing Months 3.18%

Balance Sheet

Total Cash Most Recent Quarter 23,902,000
Total Cash Past Year 27,554,000
Total Cash Prior Year 31,024,000
Net Cash Position Most Recent Quarter -24,260,000
Net Cash Position Past Year -19,942,000
Long Term Debt Past Year 47,496,000
Long Term Debt Prior Year 46,603,000
Total Debt Most Recent Quarter 48,162,000
Equity to Debt Ratio Past Year 0.69
Equity to Debt Ratio Most Recent Quarter 0.71
Total Stockholder Equity Past Year 103,907,000
Total Stockholder Equity Prior Year 95,665,000
Total Stockholder Equity Most Recent Quarter 120,805,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 2,853,000
Free Cash Flow Per Share Twelve Trailing Months 0.06
Free Cash Flow Past Year 11,000
Free Cash Flow Prior Year -20,634,000

Options

Put/Call Ratio 0.58
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 2.81
MACD Signal 2.36
20-Day Bollinger Lower Band 8.32
20-Day Bollinger Middle Band 19.91
20-Day Bollinger Upper Band 31.51
Beta 1.06
RSI 82.28
50-Day SMA 16.62
150-Day SMA 11.46
200-Day SMA 11.02

System

Modified 12/8/2025 6:14:11 PM EST